Angiotensin-(1-7) Cardiovascular Effects in Aging

Part of paid clinical trials in Hershey, Pennsylvania.

Sponsor
Milton S. Hershey Medical Center
Study ID
NCT05301192
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Aging

Eligibility Criteria

Sex
ALL
Age
65 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Angiotensin-(1-7) — DRUG
    This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
  • Saline — DRUG
    Saline will be used as the placebo comparator.

Study Details

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

Key Dates

Start date
Dec 9, 2022
Status verified
Sep 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
26 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Angiotensin-(1-7)
    Participants will receive intravenous angiotensin-(1-7) at one study visit for 110 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 80 minutes. Infusion rates will be calculated for each participant based on body mass.
  • Placebo Comparator: Saline
    Participants will receive intravenous saline at one study visit for 110 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each participant based on body mass.

Primary Outcome Measure

Change in Muscle Sympathetic Nerve Burst Rate [ Time Frame: 110 minutes ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Penn State Milton S. Hershey Medical CenterHersheyPennsylvania17033
Amy Arnold, PhD
[email protected]
717-531-3674
Urs A Leuenberger, MD (SUB_INVESTIGATOR)
Aimee Cauffman, RN (SUB_INVESTIGATOR)
Cheryl Blaha, RN (SUB_INVESTIGATOR)
Jian Cui, PhD (SUB_INVESTIGATOR)
Takuto Hamaoka, MD, PhD (SUB_INVESTIGATOR)

Find similar trials in Hershey, PA

By research site
Penn State Milton S. Hershey Medical Center· Hershey, PA

Related Studies